Supergen (SUPG) has been moving up steadily over the past few days since its low in the $2.10+ range this week.SUPG is in the Rayno Life Science Portfolio. The April 15,2010 high was $3.72.The balance sheet is strong with over $100M in cash,Shareholder Equity of $106M and no debt. Market Cap is $147M. Revenue for Q1 was $14.4M primarily from Dacogen royalties with a profit of $4.7M. Revenues are expected to be in the $41-$44M in 2010 and flat next year. The R&D pipeline in cancer therapeutics based upon  epigenetic targets is being funded with $29M primarily from existing product royalties and a partnership with Glaxo (GSK). Three products are in the pipeline with the MP-470 TK inhibitor in Phase I.

The stock is owned by several blue chip institutional investors such as Orbimed,BVF Partners, Wellington and Blackrock.

Chart forSuperGen Inc. (SUPG)

Pin It on Pinterest